Union Minister for Health and Family Welfare J. P. Nadda will launch the Tetanus and Adult Diphtheria (Td) vaccine on 21 February 2026 at the Central Research Institute (CRI), Kasauli, Himachal Pradesh.
The introduction of the Td vaccine marks a significant step in strengthening India’s immunization framework. While widespread use of DPT vaccines has substantially reduced diphtheria and tetanus cases globally, immunity—particularly against diphtheria—can decline over time, making booster protection necessary. In line with recommendations of the World Health Organization and India’s National Technical Advisory Group on Immunization (NTAGI), the country is transitioning from Tetanus Toxoid (TT) to the Td vaccine across age groups, including pregnant women.
The move aims to provide extended protection against both tetanus and diphtheria while sustaining the gains achieved in maternal and neonatal tetanus elimination. The vaccine will now be incorporated under the Universal Immunization Programme (UIP).
CRI has completed all required developmental studies and regulatory approvals for the vaccine, including marketing authorization and manufacturing licenses. Commercial production has commenced, and the vaccine has received clearance from the Central Drugs Laboratory, Kasauli. Following the launch, CRI will supply 55 lakh doses to the UIP by April 2026, with production expected to scale up in the coming years.
Tetanus is a severe disease that causes painful muscle stiffness, breathing difficulties, and can be fatal. Diphtheria is a life-threatening infection that may result in respiratory distress, heart complications, paralysis, and death. The Td vaccine—prepared using purified tetanus and diphtheria toxoids—offers combined protection and is designed to reduce illness and mortality linked to these preventable diseases.
Established in 1905 under the Directorate General of Health Services, CRI plays a key role in domestic vaccine production in alignment with India’s National Vaccine Policy. The launch of the Td vaccine is expected to strengthen indigenous manufacturing capacity and ensure sustained availability of quality-assured vaccines across the country.
Senior officials from the Ministry of Health and Family Welfare, state health departments, and public health experts will attend the launch event, where the Union Health Minister will address the gathering.



